Visit fordetails. JetBlue serves 53 cities with 600 daily flights.With JetBlue, allseats are assigned, all travel is ticketless, all fares are one-way, and anovernight stay is never required. For information or reservations call1-800-JETBLUE (1-800-538-2583), TTY/TDD 1-800-336-5530 or visit press release contains statements of a forward-looking nature whichrepresent our management's beliefs and assumptions concerning future events.Forward-looking statements involve risks, uncertainties and assumptions, andare based on information currently available to us. Further information concerning these and other factors iscontained in the Company's Securities and Exchange Commission filings,including but not limited to, the Company's 2008 Annual Report on Form 10-Kand Quarterly Reports on Form 10-Q. We undertake no obligation to update anyforward-looking statements to reflect events or circumstances that may ariseafter the date of this release. SOURCEJetBlue Airways CorporationInvestor Relations, +1-718-709-2202, ; or CorporateCommunications, +1-718-709-3089, . NEW YORK (Reuters) - Private equity firm Blackstone Group LP (BX.N) reported a quarterly loss Wednesday and said capital available to clinch buyout deals was still scarce, but shares jumped as it topped Wall Street forecasts and paid a full quarterly distribution.

Deals  |  Hot StocksBlackstone's chief operating officer, Tony James, said on a conference call the company should be able to make a full distribution of $1.20 per share this year, absent any big surprises. It is paying out 30 cents for the first quarter."The world is an uncertain place right now," James said "We believe that we'll have the fee-related earnings .. to make the dividend for the full $1.20. But we're also pretty pessimistic about the world."James said the company wrote down the value of its private equity portfolio by 3 percent in the quarter, and wrote down the value of its real estate portfolio by 19 percent. That compared with a loss of $94 million a year earlier.On an after-tax basis, its ENI loss was 7 cents a share, compared with a loss of 6 cents a year earlier. Analysts polled by Reuters expected, on average, a loss of 10 cents per share.Blackstone prefers to focus on ENI because of the big payouts associated with its more than $4 billion initial public offering in June 2007.James said Blackstone has about $27 billion of "dry powder," meaning capital available to invest.He expects Blackstone to deploy about the same amount of private equity capital this year as the $3.4 billion it spent in 2008.

Blackstone said the number of opportunities it is screening is on the rise as more companies are trying to shed assets.It also expects to be active in credit investments, deploying around $3 billion to $5 billion, James said. GlaxoSmithKline (GSK.L) said in April it would buy Stiefel for $3.6 billion.James said that Blackstone did not pitch to be one of the PPIP providers -- referring to the U.S. government's public-private effort to dispose of toxic assets. Firms such as fixed-income managements have sought to be among the managers for the public-private effort.Blackstone shares were up $1.75 or 14.4 percent at $13.91 on the New York Stock Exchange on Wednesday afternoon, after rising as much as 17 percent earlier in the session. The shares have doubled this year but are still down significantly from their June 2007 initial public offering price of $31.(Reporting by Megan Davies; editing by John Wallace and Matthew Lewis) Deals Hot Stocks. SKOKIE, IL, May 06 (MARKET WIRE) -- NanoGuardian(TM), a division of NanoInk(R) that delivers brand protectionsolutions to fight illegal diversion and counterfeiting, announced todaythat pharmaceutical security expert and co-founder of the PharmaceuticalSecurity Institute, Dr. John Glover, published a white paper extollingnecessary requirements of the Food and Drug Administration (FDA)-proposedRisk Evaluation and Mitigation Strategies (REMS) for opioid products,commonly referred to as pain medications.The white paper, entitled "The Importance of On-Dose Technologies in theFight Against Misuse, Abuse and Illegal Diversion of Opioids," addressesthe pressing need for on-dose technologies in the battle against illicitdiversion and the intentional misuse and abuse of opioid medications.